Description
Co-Trimoxazole Tablets (Single Strength / Double Strength)
Healthy Inc is a premier global supplier of high-efficacy antimicrobial therapies. We provide premium Co-Trimoxazole Tablets (Sulfamethoxazole & Trimethoprim), manufactured in WHO–GMP certified antibiotic production units. As a versatile, broad-spectrum therapeutic, this product is a cornerstone export for infectious disease clinics, community health centers, and National Health Tenders in Africa, Southeast Asia, and LATAM.
Product Overview
Co-Trimoxazole is a fixed-dose combination of two folic acid antagonists. It is specifically engineered to provide a synergistic effect that is bactericidal, whereas each component alone is primarily bacteriostatic.
The “Sequential Blockade” Specialist:
- Sulfamethoxazole: A sulfonamide that competitively inhibits the enzyme dihydropteroate synthase. It prevents the incorporation of PABA into dihydrofolic acid, the first step in bacterial folate synthesis.
- Trimethoprim: A pyrimidine derivative that binds to and reversibly inhibits dihydrofolate reductase. This blocks the second step: the reduction of dihydrofolate to tetrahydrofolate (the active form of folate).
- Synergistic Advantage: By blocking two consecutive steps in the biosynthesis of nucleic acids and proteins essential to many bacteria, Co-Trimoxazole minimizes the development of bacterial resistance and broadens the antimicrobial spectrum.
Technical & Manufacturing Specifications
Formulated for precise 5:1 ratio stability and optimized pharmacokinetic release.
| Technical Metric | Specification Standard |
|---|---|
| Active Composition | Sulfamethoxazole (400/800mg) + Trimethoprim (80/160mg) |
| Dosage Form | Uncoated or Film-Coated Tablets |
| Standard Strengths | 480 mg (SS) / 960 mg (DS) |
| HS Code | 3004.20.19 (Other Antibiotics) / 3004.90.99 |
| Regulatory Status | WHO-GMP, CTD Dossier, COPP Available |
Manufacturing Authority
Marketed and Distributed by Healthy Inc from ISO 9001:2015 certified units.
- FDC Ratio Integrity: We ensure a strict 5:1 ratio (Sulfamethoxazole to Trimethoprim) through validated blending processes, which is critical to achieving the peak plasma ratio of 20:1 required for maximum synergy.
- Solubility Optimization: Sulfamethoxazole has low aqueous solubility. Our formulation utilizes micronized particles and specialized disintegrants to ensure rapid drug release and high systemic bioavailability.
- Stability for Tropical Climates: Every batch is tested under Climatic Zone IVb conditions to ensure the tablets remain physically and chemically stable in high-humidity regions of Africa and Southeast Asia.
Therapeutic Indications & Clinical Symptoms
- Urinary Tract Infections (UTI): Treatment of cystitis and pyelonephritis caused by susceptible organisms.
- Respiratory Infections: Effective against Pneumocystis jirovecii pneumonia (PCP) and exacerbations of chronic bronchitis.
- Gastrointestinal Infections: Management of shigellosis, typhoid fever, and traveler’s diarrhea.
- Prophylaxis: Widely used for the prevention of opportunistic infections in immunocompromised/HIV-positive patients.
Dosage & Administration
- Administration: Typically administered twice daily (every 12 hours). It should be taken with adequate fluid intake to prevent crystalluria.
- Adjustment: Dosage must be adjusted in patients with impaired renal function (CrCl < 30 mL/min).
- Safety Note: Use with caution in patients with known sulfonamide allergies or folic acid deficiency.
Global Export & Contract Manufacturing Services
Healthy Inc is a verified Pharmaceutical Exporter in Mumbai, catering to GDF, Global Fund, and Ministry of Health Tenders. We offer Third Party Manufacturing for Co-Trimoxazole with customized strengths (including pediatric dispersible variants). Our logistics expertise ensures secure, high-volume supply to Nigeria, Vietnam, Kenya, and the Philippines, providing WHO-GMP quality at competitive B2B prices.
Commercial Inquiries
WhatsApp/Call: +91 7710003340
Email: info@healthyinc.co.in
